Chinese Medicine Regulatory Office

Chinese Medicines

• Announcement on the Issuance of the Second Batch of General Rules for the Chinese medicines standards and Safety Quality Control Items for Traditional Chinese Medicine in the Guangdong-Hong Kong-Macao Greater Bay Area (August 31, 2026) (Chinese version only)
• 【Guangdong Provincial Association for Science and Technology】Adhere to the "Four Strictest" Requirements and Build a Full-Chain Quality and Safety Regulatory System (30 July 2026) (Chinese version only)
• 7th Guangdong-Hong Kong-Macao Greater Bay Area Conference on Inheritance, Innovation, and Development of Traditional Chinese Medicine held in Hong Kong (with photos) (2 December 2025)
• The National Medical Products Administration (NMPA) Center for Drug Evaluation and Inspection, Greater Bay Area Sub-center, released common issues and responses regarding the streamlined Mainland registration of traditional oral proprietary Chinese medicines (pCms) already marketed in Hong Kong and Macau (29 October 2025) (Chinese version only)
• Traditional proprietary Chinese medicine from Hong Kong approved for market entry in Mainland by the National Medical Products Administration under streamlined procedures (17 October 2025) (Chinese version only)
• Secretary for Health leads delegation to Beijing (with photos) (4 September 2025)
• DH visited the Guangdong Provincial Medical Products Administration (GDMPA) to discuss the work on the innovative development of medical products regulation in Guangdong and Hong Kong. (12 Aug 2025) (Chinese version only)
• The Center for Drug Evaluation of the National Medical Products Administration (NMPA) and Guangdong-Hong Kong-Macao Greater Bay Area Center for Drug Evaluation and Inspection of NMPA issued notice on matters concerning communication and consultation services for Hong Kong and Macau registered traditional proprietary Chinese medicines (pCms) for internal use to be registered in the Mainland (19 May 2025) (Chinese version only)
• DH proactively promotes arrangement of streamlining approval procedures for HK-registered proprietary Chinese medicines for oral use to be registered on the Mainland to further promote healthcare collaboration in GBA (with photos) (28 April 2025)
• The Center for Drug Evaluation of the National Medical Products Administration (NMPA) issued "Application materials and technical requirements for Hong Kong and Macau registered traditional proprietary Chinese medicines (pCms) for internal use to be registered in the Mainland under the streamlined approval procedures" (18 April 2025) (Chinese version only)
• HKSAR Government welcomes announcement by National Medical Products Administration on arrangement of streamlining approval procedures for HK registered traditional pCms for oral use to be registered on Mainland (21 January 2025)
• The Center for Drug Evaluation of the National Medical Products Administration (NMPA) solicits public opinions on "Application materials and technical requirements for Hong Kong and Macau registered traditional proprietary Chinese medicines (pCms) for internal use to be registered in the Mainland under the streamlined approval procedures (Draft for Comments)" (31 December 2024) (Chinese version only)
• The Department of Comprehensive Affairs, Planning, and Finance Affairs of the National Medical Products Administration (NMPA) solicits public opinions on "Streamlining the approval procedures for Hong Kong and Macau registered traditional proprietary Chinese medicines (pCms) for internal use to be registered in the Mainland (Draft for Comments)" (9 December 2024) (Chinese version only)
• Secretary for Health attends Guangdong-Hong Kong-Macao Greater Bay Area Conference on Inheritance, Innovation and Development of Traditional Chinese Medicine in Dongguan (with photos) (14 November 2024)
• Secretary for Health attends 2024 GBA Medical Products Administration Conference in Zhuhai (with photos) (30 October 2024)
• Announcement on the release of the first batch of Guangdong-Hong Kong-Macao Greater Bay Area (GBA) Chinese medicines standards and general safety control test requirements (29 October 2024) (Chinese version only)
• The Guangdong Provincial Medical Products Administration (GDMPA) hosted symposium for pharmaceutical manufacturers supplying decoction pieces of Chinese Materia Medica to Hong Kong (10 July 2024) (Chinese version only)
• Symposium on developing standards for Chinese medicines in the Guangdong-Hong Kong-Macao Greater Bay Area convenes (29 May 2024) (Chinese version only)
• Secretary for Health praises DH's new dedicated Digital Herbarium for Chinese Medicines website (with photos) (26 March 2024)
• Notice regarding the situation of the approval procedures for Hong Kong and Macao registered traditional proprietary Chinese medicines for external use from the Guangdong Provincial Medical Products Administration (GDMPA) (24 January 2024) (Chinese version only)
• The workstation of the pharmacopoeia commission for the Guangdong-Hong Kong-Macao Greater Bay Area organized a Pharmacopoeia Committee symposium (13 December 2023) (Chinese version only)
• The first working meeting of the Guangdong-Hong Kong-Macao Greater Bay Area Chinese Medicine Standards Expert Committee was held in Hengqin (11 December 2023) (Chinese version only)
• Secretary for Health continues visit to Beijing (with photos) (7 November 2023)
• Secretary for Health attends 2023 GBA Medical Products Administration Conference in Zhuhai (25 October 2023)
• The International Symposium on the Application and Development of Molecular Authentication Technology for Chinese Medicinal Material was successfully hosted by the Guangdong Institute for Drug Control (GDIDC) (15 August 2023) (Chinese version only)
• The first Hong Kong / Macau registered proprietary Chinese medicine for external use, produced and sold in Mainland, is now produced for marketing in Jiangmen (21 July 2023) (Chinese version only)
• S for Health meets Guangdong Provincial Medical Products Administration delegation (with photos) (27 March 2023)
• Health Bureau and Department of Health meet National Medical Products Administration delegation (with photos) (13 February 2023)
• Forum on Drug Evaluation and Inspection affairs in the Guangdong-Hong Kong-Macao Greater Bay Area (9 November 2022)
• The Department of General Affairs of the National Medical Products Administration Issued the "Implementation Plan for Supporting Hong Kong and Macau Drug Marketing Authorization Holders to Produce Drugs in 9 Mainland Cities of the Greater Bay Area" (23 June 2022)
• Documents required in applying for registration of locally manufactured pCms for export only(27 May 2022)
• The Guangdong Provincial Medical Products Administration (GDMPA) issued registration certificates for the Mainland market for the second batch of Hong Kong / Macau registered traditional proprietary Chinese medicines for external use (12 April 2022) (Chinese version only)
• The Guangdong Provincial Medical Products Administration (GDMPA) hosted the seminar on Reform of the Marketing Authorization Holder (MAH) System in the Guangdong-Hong Kong-Macao Greater Bay Area (GBA) (2 April 2022) (Chinese version only)
• Guangdong Provincial Medical Products Administration (GDMPA) hosted an in-depth seminar to promote the innovation and international development of Chinese Medicines in the Guangdong-Hong Kong-Macao Greater Bay Area (GBA) (18 March 2022) (Chinese version only)
• FHB welcomes approval of first batch of products for sale in Mainland under streamlined procedures for HK registered traditional pCms for external use to be registered in GBA(31 December 2021)
• Streamlining approval procedures for HK registered traditional pCms for external use to be registered in GBA (29 September 2021)
• Guangdong Provincial Medical Products Administration (GDMPA) actively participated in the promotion for the medical and health and Chinese Medicine policies from Mainland in Hong Kong region (13 September 2021) (Chinese version only)